MAFLD
Clinical trials for MAFLD explained in plain language.
Never miss a new study
Get alerted when new MAFLD trials appear
Sign up with your email to follow new studies for MAFLD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to tackle diabetes and fatty liver together
Disease control Not yet recruitingThis study tests whether adding alogliptin to two common diabetes drugs (pioglitazone and metformin) works better than the two-drug combination alone for people with type 2 diabetes who also have fatty liver disease. The goal is to improve blood sugar control, fat levels, and pan…
Matched conditions: MAFLD
Phase: PHASE4 • Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated May 26, 2026 04:41 UTC
-
Could a daily pill slow kidney failure in fatty liver patients?
Disease control Not yet recruitingThis study looks at whether oral semaglutide, a drug already used for diabetes, can slow kidney disease in people who also have fatty liver disease. About 90 adults with both conditions will receive either the drug or standard care for 2 years. Researchers will track kidney funct…
Matched conditions: MAFLD
Phase: NA • Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Gut health and gym: a new hope for fatty liver?
Disease control Not yet recruitingThis study looks at whether combining probiotics (good bacteria) with resistance exercise can help people with fatty liver disease. The goal is to reduce liver fat and improve health. 180 adults aged 18-60 with fatty liver will take part. Researchers will also check if the body's…
Matched conditions: MAFLD
Phase: NA • Sponsor: Nicolaus Copernicus University • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Rhubarb drug shows promise against fatty liver in new trial
Disease control Not yet recruitingThis study tests whether diacerein, a drug made from a compound found in rhubarb, can help treat metabolic fatty liver disease (MAFLD) in adults. About 74 people will receive either the drug or a placebo to see if it safely reduces liver fat and improves liver function. The goal …
Matched conditions: MAFLD
Phase: NA • Sponsor: Hongyan Wu • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New handheld liver scanner put to the test against standard device
Knowledge-focused Not yet recruitingThis study will check if a new handheld device can accurately measure liver stiffness and fat in adults with chronic liver disease, compared to a standard device called iLivTouch. About 224 participants will be tested with both devices while lying down and sitting. The goal is to…
Matched conditions: MAFLD
Sponsor: Hong You • Aim: Knowledge-focused
Last updated May 26, 2026 04:33 UTC